Late Rakesh Jhunjhunwala Portfolio, now managed by his wife Rekha Jhunjhunwala, has faced significant losses amid recent stock market fluctuations. Over the past two months, the portfolio’s value has declined by approximately ₹15,000 crore, dropping from ₹55,095.90 crore at the end of September to ₹40,082.90 crore as of mid-November.
This 13% dip in the portfolio outpaces the broader market declines, as the Sensex and Nifty have shed 8-9% over the same period. Notably, the family’s top five holdings—Titan Company, Tata Motors, Concord Biotech, Star Health and Allied Insurance, and Metro Brands—have all suffered significant downturns.
Top 3 Stocks Under Pressure
1. Tata Motors
Decline: 20% since September 30
Tata Motors faced setbacks primarily due to its Jaguar Land Rover (JLR) division. While JLR maintained its FY25 EBIT margin guidance at 8.5%, it lowered free cash flow expectations from £1.8 billion to £1.3 billion, citing increased capital expenditure. Declining gross margins and higher marketing expenses have added to investor concerns, despite a favorable product mix.
Star Health and Allied Insurance
Decline: 24%
Star Health’s shares have been impacted by a rise in claim ratios, which increased by 410 basis points in Q2 due to prolonged monsoons and a spike in critical illness cases. Analysts believe operational scale could eventually reduce expense ratios, but loss ratios remain contingent on pricing strategies and product mix. Despite these challenges, brokerages like MOFSL maintain a positive outlook with a target price of ₹630.
Titan Company Limited
Decline: 15.8% since September 30
Titan’s shares have taken a hit, largely due to underwhelming Q2 performance. Weak margins in the jewelry segment and reduced margin guidance for FY25 have fueled investor concerns. Analysts attribute the decline to custom duty cuts, which boosted jewelry sales but negatively impacted reported margins.
Should Investors Be Worried?
The steep decline in the Jhunjhunwala family portfolio may raise concerns among investors, especially those tracking its holdings as benchmarks. However, market analysts suggest adopting a long-term perspective rather than reacting to short-term fluctuations.
Cyclical Challenges:
Stocks like Titan and Tata Motors have faced sector-specific challenges such as weaker margins and reduced free cash flow guidance. These are cyclical issues that often accompany economic transitions and market volatility.
Sectoral Resilience:
Despite the current downturn, many of these companies operate in sectors with strong long-term growth potential. For example, Titan benefits from India’s growing demand for luxury goods, while Tata Motors is well-positioned to capitalize on the transition to electric vehicles (EVs).
Expert Opinions:
Analysts remain optimistic about the recovery prospects of some of these stocks. For instance, MOFSL’s “buy” rating for Star Health suggests confidence in the company’s ability to address operational challenges over time.
While the portfolio’s performance reflects immediate pressures, its diversified nature and focus on fundamentally sound companies provide a cushion against prolonged downturns. Investors are advised to focus on the broader economic trends and company-specific recovery strategies rather than panic-selling during volatility.
In conclusion, while short-term losses may appear daunting, the portfolio’s strong underlying assets and market positioning suggest that patience could reward long-term investors.
Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice. Investors should conduct thorough research or consult financial advisors before making investment decisions. The information provided is based on publicly available data and may be subject to change. The authors and publishers are not responsible for any financial outcomes based on this article.